Key facts
- This page summarizes David C. Hodgson's Form 4 filing for Royalty Pharma plc (RPRX).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Jun 2026, 16:26.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Additional SEC filing notes
Footnote F1
Reflects an award of restricted stock units under the Issuer's 2020 Independent Director Equity Incentive Plan (the "Plan") that is generally scheduled to vest 100% on the earlier of (i) the one-year anniversary of the grant date and (ii) the date of the annual meeting of the Issuer's shareholders in the first calendar year following the grant date, subject to the terms of the Plan and the applicable award agreement thereunder. The restricted stock units granted to the Reporting Person are held by him solely for the benefit of General Atlantic Service Company, L.P. The Reporting Person disclaims beneficial ownership of the restricted stock units in the underlying shares.
SEC remarks
In addition to the Class A Ordinary Shares disclosed above, the Reporting Person holds limited partnership interests in RPI US Partners 2019, LP exchangeable into 79,476 Class A Ordinary Shares.